Terence Flynn
Stock Analyst at Morgan Stanley
(4.27)
# 525
Out of 4,412 analysts
145
Total ratings
59.49%
Success rate
11.45%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $168 → $167 | $146.82 | +13.74% | 16 | Apr 17, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $9 → $10 | $12.47 | -19.81% | 3 | Feb 26, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Underweight | $46 → $48 | $54.83 | -12.46% | 6 | Feb 26, 2024 | |
| CCCC C4 Therapeutics | Maintains: Equal-Weight | $1 → $8 | $6.32 | +26.58% | 5 | Feb 26, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $805 → $950 | $737.20 | +28.87% | 15 | Feb 16, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $281 → $278 | $276.38 | +0.59% | 3 | Feb 7, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $38 → $35 | $15.63 | +123.93% | 3 | Nov 13, 2023 | |
| ARVN Arvinas | Maintains: Equal-Weight | $32 → $20 | $31.90 | -37.30% | 7 | Nov 13, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $90 → $85 | $21.98 | +286.72% | 4 | Nov 13, 2023 | |
| RPRX Royalty Pharma | Maintains: Overweight | $54 → $57 | $28.12 | +102.70% | 10 | Nov 9, 2023 | |
| UTHR United Therapeutics | Maintains: Overweight | $318 → $314 | $238.26 | +31.79% | 7 | Nov 2, 2023 | |
| PFE Pfizer | Maintains: Equal-Weight | $39 → $37 | $25.64 | +44.31% | 12 | Nov 1, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $193 → $196 | $161.52 | +21.35% | 9 | Oct 30, 2023 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $115 → $118 | $130.12 | -9.31% | 12 | Oct 27, 2023 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $56 → $50 | $44.64 | +12.01% | 9 | Oct 27, 2023 | |
| RVNC Revance Therapeutics | Maintains: Equal-Weight | $25 → $12 | $3.69 | +225.20% | 7 | Oct 11, 2023 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $27 → $22 | $18.90 | +16.40% | 7 | Oct 11, 2023 | |
| BPMC Blueprint Medicines | Maintains: Buy | $93 → $83 | $93.10 | -10.85% | 4 | Aug 3, 2023 | |
| BIIB Biogen | Maintains: Neutral | n/a | $215.50 | - | 3 | Jun 14, 2021 | |
| TBIO Telesis Bio | Initiates: Buy | n/a | $0.34 | - | 1 | Oct 5, 2020 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | n/a | $147.36 | - | 1 | Oct 2, 2017 | |
| FGEN FibroGen | Downgrades: Neutral | n/a | $1.09 | - | 1 | Jul 21, 2017 |
Johnson & Johnson
Apr 17, 2024
Maintains: Equal-Weight
Price Target: $168 → $167
Current: $146.82
Upside: +13.74%
Nurix Therapeutics
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $12.47
Upside: -19.81%
CRISPR Therapeutics AG
Feb 26, 2024
Maintains: Underweight
Price Target: $46 → $48
Current: $54.83
Upside: -12.46%
C4 Therapeutics
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $6.32
Upside: +26.58%
Eli Lilly
Feb 16, 2024
Maintains: Overweight
Price Target: $805 → $950
Current: $737.20
Upside: +28.87%
Amgen
Feb 7, 2024
Maintains: Equal-Weight
Price Target: $281 → $278
Current: $276.38
Upside: +0.59%
Arcus Biosciences
Nov 13, 2023
Maintains: Overweight
Price Target: $38 → $35
Current: $15.63
Upside: +123.93%
Arvinas
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $32 → $20
Current: $31.90
Upside: -37.30%
Intellia Therapeutics
Nov 13, 2023
Maintains: Overweight
Price Target: $90 → $85
Current: $21.98
Upside: +286.72%
Royalty Pharma
Nov 9, 2023
Maintains: Overweight
Price Target: $54 → $57
Current: $28.12
Upside: +102.70%
United Therapeutics
Nov 2, 2023
Maintains: Overweight
Price Target: $318 → $314
Current: $238.26
Upside: +31.79%
Pfizer
Nov 1, 2023
Maintains: Equal-Weight
Price Target: $39 → $37
Current: $25.64
Upside: +44.31%
AbbVie
Oct 30, 2023
Maintains: Overweight
Price Target: $193 → $196
Current: $161.52
Upside: +21.35%
Merck & Co.
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $115 → $118
Current: $130.12
Upside: -9.31%
Bristol-Myers Squibb Company
Oct 27, 2023
Maintains: Underweight
Price Target: $56 → $50
Current: $44.64
Upside: +12.01%
Revance Therapeutics
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $25 → $12
Current: $3.69
Upside: +225.20%
Organon & Co.
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $27 → $22
Current: $18.90
Upside: +16.40%
Blueprint Medicines
Aug 3, 2023
Maintains: Buy
Price Target: $93 → $83
Current: $93.10
Upside: -10.85%
Biogen
Jun 14, 2021
Maintains: Neutral
Price Target: n/a
Current: $215.50
Upside: -
Telesis Bio
Oct 5, 2020
Initiates: Buy
Price Target: n/a
Current: $0.34
Upside: -
Alnylam Pharmaceuticals
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $147.36
Upside: -
FibroGen
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $1.09
Upside: -